CDKN2A and acute myeloid leukemia: To gain further insight into molecular features of the engineered AML-initiating cells we used RNA sequencing to compare gene expression between primary renal cell cultures 5 days after infection with control or shRNA-Tsc2 + Cdkn2a viruses and spheres derived from shRNA-Tsc2 + Cdkn2a-infected cells harvested 12 days after infection (Fig. 3a).